LFCR (Lifecore Biomedical) EBIT: $-6.12 Mil (TTM As of Mar. 2026)

Lifecore Biomedical  (NAS:LFCR) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Lifecore Biomedical's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

where

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Lifecore Biomedical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

where Working Capital is:

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Lifecore Biomedical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lifecore Biomedical EBIT Related Terms

The historical data trend for Lifecore Biomedical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lifecore Biomedical EBIT Chart

Lifecore Biomedical Annual Data
	Trend	May16	May17	May18	May19	May20	May21	May22	May23	May24	May25
EBIT		Get a 7-Day Free Trial					-20.85	-5.22	-46.35	27.66	-16.51

Lifecore Biomedical Quarterly Data
	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24	Nov24	Feb25	May25	Sep25	Dec25	Mar26
EBIT	Get a 7-Day Free Trial															-9.19	4.74	-3.27	0.00	-7.59

LFCR vs ANIK, DERM, ASRT: EBIT Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lifecore Biomedical EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Lifecore Biomedical's EV-to-EBIT falls into.

Lifecore Biomedical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-6.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lifecore Biomedical Business Description